No value in raising HDL cholesterol

Pharmaceutical companies appear to  be barking up the wrong tree by developing drugs that increase levels of  HDL-cholesterol.

None of the three classes of drug show any benefit on clinical endpoints such as mortality, heart attacks or stroke, according to a meta-analysis published by The BMJ.

The findings show the HDL-raising hypothesis underpinning the "next frontier" of preventive cardiovascular medicine is simplistic and incorrect, writes cardiologist Dr Daniel Keene of Imperial College,